Cargando…
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
INTRODUCTION: Monoaminergic activity modulates nociceptive transmission in the central nervous system (CNS). Although pain is the most disabling symptom of osteoarthritis (OA), limited knowledge exists regarding the CNS mechanisms that amplify pain and drive sensitization processes in humans. OBJECT...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789209/ https://www.ncbi.nlm.nih.gov/pubmed/35097309 http://dx.doi.org/10.1097/PR9.0000000000000988 |
_version_ | 1784639717525946368 |
---|---|
author | Bjurström, Martin F. Blennow, Kaj Zetterberg, Henrik Bodelsson, Mikael Waldén, Markus Dietz, Nicholas Hall, Sara Hansson, Oskar Irwin, Michael R. Mattsson-Carlgren, Niklas |
author_facet | Bjurström, Martin F. Blennow, Kaj Zetterberg, Henrik Bodelsson, Mikael Waldén, Markus Dietz, Nicholas Hall, Sara Hansson, Oskar Irwin, Michael R. Mattsson-Carlgren, Niklas |
author_sort | Bjurström, Martin F. |
collection | PubMed |
description | INTRODUCTION: Monoaminergic activity modulates nociceptive transmission in the central nervous system (CNS). Although pain is the most disabling symptom of osteoarthritis (OA), limited knowledge exists regarding the CNS mechanisms that amplify pain and drive sensitization processes in humans. OBJECTIVES: The main objective of this study was to evaluate associations between cerebrospinal fluid (CSF) monoamine metabolites, pain severity, and central sensitization in patients with OA undergoing total hip arthroplasty (THA). METHODS: Patients with OA (n = 52) and pain-free controls (n = 30) provided CSF samples for measurement of serotonin (5-hydroxyindoleacetic acid [5-HIAA]), noradrenaline (3-methoxy-4-hydroxyphenylglycol [HMPG]), and dopamine (homovanillic acid [HVA]) monoamine metabolites. Patients with OA completed longitudinal evaluation of pain using clinical measures and quantitative sensory testing. RESULTS: Patients with OA had higher HMPG levels when compared with controls (P = 0.036). Within patients with OA undergoing THA, higher 5-HIAA and HVA levels were consistently associated with higher preoperative pain severity. Higher concentrations of 5-HIAA and HVA were also associated with lower conditioned pain modulation levels, whereas higher HMPG levels were linked to more efficient conditioned pain modulation. Patients with higher levels of CSF HVA exhibited increased pressure pain sensitivity (arm pressure pain detection threshold < 250 kPa vs ≥ 250 kPa, P = 0.042). Higher preoperative levels of CSF 5-HIAA predicted poorer pain control 6 months postoperatively (brief pain inventory pain severity; adjusted β = 0.010, 95% CI 0.001–0.019). CONCLUSIONS: In OA patients with disabling pain, higher CSF levels of serotonin and dopamine metabolites are associated with increased pain severity and central sensitization. Increased noradrenergic activity may be associated with more efficient pain inhibitory capacity. |
format | Online Article Text |
id | pubmed-8789209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-87892092022-01-27 Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization Bjurström, Martin F. Blennow, Kaj Zetterberg, Henrik Bodelsson, Mikael Waldén, Markus Dietz, Nicholas Hall, Sara Hansson, Oskar Irwin, Michael R. Mattsson-Carlgren, Niklas Pain Rep Musculoskeletal INTRODUCTION: Monoaminergic activity modulates nociceptive transmission in the central nervous system (CNS). Although pain is the most disabling symptom of osteoarthritis (OA), limited knowledge exists regarding the CNS mechanisms that amplify pain and drive sensitization processes in humans. OBJECTIVES: The main objective of this study was to evaluate associations between cerebrospinal fluid (CSF) monoamine metabolites, pain severity, and central sensitization in patients with OA undergoing total hip arthroplasty (THA). METHODS: Patients with OA (n = 52) and pain-free controls (n = 30) provided CSF samples for measurement of serotonin (5-hydroxyindoleacetic acid [5-HIAA]), noradrenaline (3-methoxy-4-hydroxyphenylglycol [HMPG]), and dopamine (homovanillic acid [HVA]) monoamine metabolites. Patients with OA completed longitudinal evaluation of pain using clinical measures and quantitative sensory testing. RESULTS: Patients with OA had higher HMPG levels when compared with controls (P = 0.036). Within patients with OA undergoing THA, higher 5-HIAA and HVA levels were consistently associated with higher preoperative pain severity. Higher concentrations of 5-HIAA and HVA were also associated with lower conditioned pain modulation levels, whereas higher HMPG levels were linked to more efficient conditioned pain modulation. Patients with higher levels of CSF HVA exhibited increased pressure pain sensitivity (arm pressure pain detection threshold < 250 kPa vs ≥ 250 kPa, P = 0.042). Higher preoperative levels of CSF 5-HIAA predicted poorer pain control 6 months postoperatively (brief pain inventory pain severity; adjusted β = 0.010, 95% CI 0.001–0.019). CONCLUSIONS: In OA patients with disabling pain, higher CSF levels of serotonin and dopamine metabolites are associated with increased pain severity and central sensitization. Increased noradrenergic activity may be associated with more efficient pain inhibitory capacity. Wolters Kluwer 2022-01-24 /pmc/articles/PMC8789209/ /pubmed/35097309 http://dx.doi.org/10.1097/PR9.0000000000000988 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Musculoskeletal Bjurström, Martin F. Blennow, Kaj Zetterberg, Henrik Bodelsson, Mikael Waldén, Markus Dietz, Nicholas Hall, Sara Hansson, Oskar Irwin, Michael R. Mattsson-Carlgren, Niklas Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
title | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
title_full | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
title_fullStr | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
title_full_unstemmed | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
title_short | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
title_sort | central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization |
topic | Musculoskeletal |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789209/ https://www.ncbi.nlm.nih.gov/pubmed/35097309 http://dx.doi.org/10.1097/PR9.0000000000000988 |
work_keys_str_mv | AT bjurstrommartinf centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT blennowkaj centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT zetterberghenrik centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT bodelssonmikael centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT waldenmarkus centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT dietznicholas centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT hallsara centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT hanssonoskar centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT irwinmichaelr centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization AT mattssoncarlgrenniklas centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization |